The net worth of the reprocessed medical devices market in the Asia Pacific region is expected to be USD 428.4 million in 2023. By 2033, the market is estimated to reach USD 1,639.4 million, expanding at a CAGR of 14.4% in the meantime.
Practitioners in the healthcare sector are exploring the idea of deploying medical devices that are composed of previously used or reprocessed medical devices. This approach is gaining extreme importance with the increasing amounts of medical debris, which is escalating at an alarming speed.
The Market is being Spearheaded by:
Market Growth is Challenged by:
Abounding Opportunities for Manufacturers:
Attributes | Details |
---|---|
Asia Pacific Reprocessed Medical Devices Market Size (2022) | USD 381.8 million |
Asia Pacific Reprocessed Medical Devices Market Size (2023) | USD 428.4 million |
Asia Pacific Reprocessed Medical Devices Market Projected Size (2033) | USD 1,639.4 million |
Value CAGR (2023 to 2033) | 14.4% |
Value CAGR (2018 to 2022) | 10.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In the historical timeframe, the market observed a market valuation of USD 381.8 million in 2022. Within the historical period, the market expanded at a CAGR of 10.1%.
Surge in the medical waste resulted in the adoption of reprocessed medical devices. Since its inception, reprocessed medical devices have been rising in developed as well as developing economies. Their heightened utilization is driven by factors like government initiatives to diminish waste generation from medical devices and escalating development of reprocessed devices and services.
Over the forecast period, the market is projected to be driven by increasing awareness pertaining to sustainable healthcare practices. Exploration of new markets and strategies to boost automated pharmaceutical workflow and encourage medical device reprocessing systems are projected to aid market growth.
Heightened focus on the reduction of emissions related to the use of medical devices is projected to augment the Asia Pacific market for reprocessed medical devices. Take for example, in January 2021, researchers from the environmental safety division of Fraunhofer-Gesellschaft announced that by deploying a reprocessed medical catheter as a substitute, global warming impact was reduced by 50.4%.
From 2023 to 2033, the market is projected to register a CAGR of 14.4%. In 2023, the market is anticipated to reach USD 428.4 million, and by 2033, the market is projected to attain USD 1,639.4 million.
Country | Australia |
---|---|
Value Share % (2022) | 11.7% |
Forecast CAGR % (2023 to 2033) | 14.2% |
Country | New Zealand |
---|---|
Value Share % (2022) | 2.8% |
Forecast CAGR % (2023 to 2033) | 12.9% |
Country | China |
---|---|
Value Share % (2022) | 18.9% |
Forecast CAGR % (2023 to 2033) | 18.8% |
Country | India |
---|---|
Value Share % (2022) | 12.5% |
Forecast CAGR % (2023 to 2033) | 18% |
Country | South East Asia |
---|---|
Value Share % (2022) | 15.3% |
Forecast CAGR % (2023 to 2033) | 14.8% |
Country | Japan |
---|---|
Value Share % (2022) | 29.4% |
Forecast CAGR % (2023 to 2033) | 11.9% |
Japan has acquired a massive share of 29.4% in the Asia Pacific reprocessed medical devices industry. Due to its high maturity levels in the market, the Japan market is projected to assume a comparatively low CAGR over the forecast period, i.e., 11.9%. The market growth in the country can be attributed to the focused concentration on technical advances. Additionally, the established healthcare infrastructure in Japan is also giving impetus to market growth. Environmental considerations and cost-saving measures by the Japanese government are also fueling the adoption of reprocessed medical devices.
Following Japan, China holds a significant portion of the market. In 2022, China reprocessed medical devices industry gained an 18.9% market share. Over the forecast period, the China market is projected to leap at a CAGR of 18.8%. The market is driven by:
South East Asia obtained a 15.3% market share in 2022. In the assessment period, South East Asia is projected to expand at a CAGR of 14.8%. The market is being driven by the complex healthcare infrastructure. Moreover, the governmental encouragement for sustainable healthcare practices to develop a supportive environment for the adoption of reprocessed medical instruments is also projected to boost the market growth.
The India reprocessed medical devices industry displayed a market share of 12.5% value share in 2022. Over the foreseeing years, the market is projected to expand at 18% CAGR. The propelling healthcare sector in the country offers several opportunities for the acceptance of reprocessed medical devices. The large population in India, surging cognizance about cost-effective healthcare solutions, and increasing healthcare expenditure are all projected to expand the Indian market.
Australia acquired an 11.7% value share in 2022. In the review period, the market is anticipated to expand at 14.2% CAGR. The market is propelled by:
Segment | Cardiology Devices |
---|---|
Market Share (2022) | 59.52% |
Based on devices, cardiology devices gained a value share of 59.52% in the Asia Pacific reprocessed medical devices industry in 2022. Increasing cases of cardiovascular conditions are increasing the demand for cardiology devices like catheters, pacemakers, defibrillators, etc. Reprocessing these devices minimizes the costs and ascertains the presence of these life-saving equipment for patients in need.
Segment | Hospitals |
---|---|
Market Share (2022) | 53.64% |
Hospitals gained a 53.64% market share in 2022. Hospitals are expected to observe a high adoption rate of reprocessed medical devices owing to surging hospital expenses. In addition to this, supportive government policies for these devices are also projected to have a positive impact on the segment growth.
Companies providing reprocessed medical devices are coming into joint ventures, collaborations, and other strategies, to enhance their market share. This also offers the advantage of improving their offering for reprocessed medical devices.
Market leaders are witnessing organic as well as inorganic activities to expand their growth in the market. For example, Medline Industries reported in July 2021 that its Medline ReNewal division of medical device reprocessing attained a new milestone by successfully gaining 5.3 million medical devices for reprocessing. This diverted above one million pounds of waste from landfills and avoided around 1,500 metric tons of carbon dioxide from being released into the air. Such initiatives assisted the company in efficiently reducing medical waste.
Several firms acquired or partnered with other firms to efficiently manage expenses and enhance the quality of the deliverables. For example, Innovative Health collaborated with Acutus Medical in October 2019 to offer advanced electrophysiology (EP) technology to enhance patient outcomes in a cost-efficient manner. With this partnership, both companies delivered healthcare providers an entire array of EP products, consisting of a broad portfolio of reprocessed EP devices.
Previously, in September 2018, Vanguard acquired Pioneer Medical Devices AG to improve its medical device reprocessing services. This assisted the corporation in broadening its product portfolio.
Key Players
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2018 to 2022 |
Market Analysis | USD million for Value and MT for Volume |
Region Covered | Asia Pacific |
Key Countries Covered | China, Japan, Australia, India, South East Asia, New Zealand, The Rest of the Asia Pacific |
Key Segments Covered | Product Type, Classification, Reprocessing Method, End User, and Countries |
Key Companies Profiled | Stryker Sustainability Solutions, Inc.; Medline ReNewal; Hygia Health Services, Inc.; Cleanpart GmbH; ReNu Medical, Inc.; SureTek Medical; NEScientific; Others |
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
The market is projected to reach USD 1,639.4 million by 2033.
Medline ReNewal and Hygia Health Services, Inc. are the top players in the market.
Japan is projected to hold a sizeable market share over the forecast period.
The market is projected to register a CAGR of 14.4% through 2033.
The market value is expected to be USD 428.4 million in 2023.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Gastroenterology Devices 5.2. Cardiology Devices 5.3. Laparoscopy Devices 5.4. Orthopaedic/Arthroscopic Devices 5.5. ENT Devices 5.6. Others 5.6.1. Pulse Oximetry Sensors 5.6.2. Ultrasound Catheters 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Classification 6.1. Critical 6.2. Semi-Critical 6.3. Non-Critical 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Reprocessing Method 7.1. In-House 7.2. Third Party Assisted 7.3. Non-Compliant Reprocessors 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 8.1. Hospitals 8.2. Diagnostic Centres 8.3. Ambulatory Surgical Centres 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. Asia Pacific 9.5. MEA 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Stryker Corporation 17.2. Medline Industries, Inc. 17.3. Johnson & Johnson (Ethicon) 17.4. Medtronic plc 17.5. Sterilmed, Inc. (a part of Johnson & Johnson) 17.6. Centurion Medical Products Corporation 17.7. Vanguard AG 17.8. ReNu Medical Inc. 17.9. SureTek Medical 17.10. Centurion Systems Pty Ltd. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports